全文获取类型
收费全文 | 177篇 |
免费 | 6篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 3篇 |
基础医学 | 38篇 |
口腔科学 | 2篇 |
临床医学 | 6篇 |
内科学 | 20篇 |
神经病学 | 38篇 |
特种医学 | 5篇 |
外科学 | 18篇 |
综合类 | 1篇 |
预防医学 | 11篇 |
眼科学 | 8篇 |
药学 | 8篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 5篇 |
2014年 | 6篇 |
2013年 | 6篇 |
2012年 | 11篇 |
2011年 | 10篇 |
2010年 | 8篇 |
2009年 | 4篇 |
2008年 | 8篇 |
2007年 | 9篇 |
2006年 | 7篇 |
2005年 | 6篇 |
2004年 | 11篇 |
2003年 | 12篇 |
2002年 | 14篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1998年 | 5篇 |
1997年 | 5篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1978年 | 2篇 |
排序方式: 共有183条查询结果,搜索用时 15 毫秒
1.
Tatsuaki Takeda Hiromasa Yamamoto Ken Suzawa Shuta Tomida Shunsaku Miyauchi Kota Araki Kentaro Nakata Akihiro Miura Kei Namba Kazuhiko Shien Junichi Soh Tadahiko Shien Yoshihisa Kitamura Toshiaki Sendo Shinichi Toyooka 《Cancer science》2020,111(3):849-856
Molecular‐targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2‐positive breast cancer. However, acquired resistance of various cancers to molecular‐targeted drugs is an issue of clinical concern, and emergence of resistance to neratinib is also considered inevitable. In this study, we established various types of neratinib‐resistant cell lines from HER2‐amplified breast and lung cancer cell lines using several drug exposure conditions. We analyzed the mechanisms of emergence of the resistance in these cell lines and explored effective strategies to overcome the resistance. Our results revealed that amplification of YES1, which is a member of the SRC family, was amplified in two neratinib‐resistant breast cancer cell lines and one lung cancer cell line. Knockdown of YES1 by siRNA and pharmacological inhibition of YES1 by dasatinib restored the sensitivity of the YES1‐amplified cell lines to neratinib in vitro. Combined treatment with dasatinib and neratinib inhibited tumor growth in vivo. This combination also induced downregulation of signaling molecules such as HER2, AKT and MAPK. Our current results indicate that YES1 plays an important role in the emergence of resistance to HER2‐targeted drugs, and that dasatinib enables such acquired resistance to neratinib to be overcome. 相似文献
2.
Osamu Kikuchi Shinya Ohashi Yukie Nakai Shunsaku Nakagawa Kazuaki Matsuoka Takashi Kobunai Teiji Takechi Yusuke Amanuma Masahiro Yoshioka Tomomi Ida Yoshihiro Yamamoto Yasushi Okuno Shin’ichi Miyamoto Hiroshi Nakagawa Kazuo Matsubara Tsutomu Chiba Manabu Muto 《American journal of cancer research》2015,5(8):2431-2440
5-Fluorouracil (5-FU) is a key drug for the treatment of esophageal squamous cell carcinoma (ESCC); however, resistance to it remains a critical limitation to its clinical use. To clarify the mechanisms of 5-FU resistance of ESCC, we originally established 5-FU-resistant ESCC cells, TE-5R, by step-wise treatment with continuously increasing concentrations of 5-FU. The half maximal inhibitory concentration of 5-FU showed that TE-5R cells were 15.6-fold more resistant to 5-FU in comparison with parental TE-5 cells. TE-5R cells showed regional copy number amplification of chromosome 1p including the DPYD gene, as well as high mRNA and protein expressions of dihydropyrimidine dehydrogenase (DPD), an enzyme involved in 5-FU degradation. 5-FU treatment resulted in a significant decrease of the intracellular 5-FU concentration and increase of the concentration of α-fluoro-ureidopropionic acid (FUPA), a metabolite of 5-FU, in TE-5R compared with TE-5 cells in vitro. Conversely, gimeracil, a DPD inhibitor, markedly increased the intracellular 5-FU concentration, decreased the intracellular FUPA concentration, and attenuated 5-FU resistance of TE-5R cells. These results indicate that 5-FU resistance of TE-5R cells is due to the rapid degradation of 5-FU by DPD overexpression. The investigation of 5-FU-resistant ESCC with DPYD gene copy number amplification and consequent DPD overexpression may generate novel biological evidence to explore strategies against ESCC with 5-FU resistance. 相似文献
3.
Kanaoka T Tamura K Moriya T Tanaka K Konno Y Kondoh S Toyoda M Umezono T Fujikawa T Ohsawa M Dejima T Maeda A Wakui H Haku S Yanagi M Mitsuhashi H Ozawa M Okano Y Ogawa N Yamakawa T Mizushima S Suzuki D Umemura S 《Clinical and experimental hypertension (New York, N.Y. : 1993)》2011,33(4):255-263
Accumulating evidence has shown that diabetic patients are increasing in number, and renal and cardiovascular complications are the most common cause of death in diabetic patients. Thus, it would be of considerable value to identify the mechanisms involved in the progression of renal impairment and cardiovascular injury associated with diabetes. Recent evidence also indicated that multifactorial intervention is able to reduce the risk of cardiovascular disease and death among patients with diabetes and microalbuninuria. In this pilot study, we examined the effects of intensified multifactorial intervention, with tight glucose regulation and the use of valsartan and fluvastatin on ambulatory blood pressure (BP) profile, estimated glomerular filtration rate (eGFR), and urinary albumin to creatinine ratio (UACR), in 20 hypertensive patients (16 male and 4 female) with type 2 diabetes mellitus and overt nephropathy. After 12 months of intensified treatment, office BP, fasting plasma glucose (FPG), and low-density lipoprotein cholesterol (LDLC) were significantly decreased compared to baseline (systolic blood pressure (SBP), 130 ± 2 vs. 150 ± 1 mmHg; diastolic blood pressure (DBP), 76 ± 1 vs. 86 ± 1 mmHg; FPG, 117 ± 5 vs. 153 ± 7 mg/dl; LDLC, 116 ± 8 vs. 162 ± 5 mg/dl, P < 0.0001). Also, compared to the baseline values, the daytime and nighttime ambulatory BP and short-term BP variability were significantly decreased after 12 months. Furthermore, while eGFR was not altered (44.3 ± 5.1 vs. 44.3 ± 6.5 ml/min/1.73 m(2), not significant (NS)), UACR showed a significant reduction after 12 months of intensified treatment (1228 ± 355 vs. 2340 ± 381 mg/g-cr, P < 0.05). These results suggest that the intensified multifactorial intervention is able to improve ambulatory BP profile, preserve renal function, and reduce urinary albumin excretion in type 2 diabetic hypertensive patients with overt nephropathy. 相似文献
4.
Kanae Sakakibara Yoshiki Okayama Kenji Fukushima Shunsaku Kaji Michiko Muraoka Yujiro Arao Akira Shimada 《Pediatrics international》2015,57(5):1023-1024
Congenital factor VII (FVII) deficiency is a rare bleeding disorder with autosomal recessive inheritance. The present female patient was diagnosed with congenital FVII deficiency because of low hepaplastin test (HPT), although vitamin K was given. Heterozygous p.A191T mutation was detected in the peripheral blood, and the same mutation was also found in the mother and sister. To the best of our knowledge, this is the fourth reported case of p.A191T mutation of FVII in the literature and the first to be reported in Japan. FVII coagulation activity (FVII:C) in asymptomatic heterozygous carriers is mildly reduced. Therefore, some patients may not be accurately diagnosed with congenital FVII deficiency. In infants with low HPT without vitamin K deficiency, congenital FVII deficiency should be considered. 相似文献
5.
Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men 总被引:3,自引:0,他引:3
Mizushima S Ohshige K Watanabe J Kimura M Kadowaki T Nakamura Y Tochikubo O Ueshima H 《American journal of hypertension》2004,17(8):701-706
BACKGROUND: A double-blind randomized controlled trial was carried out to assess the effect of sour milk, containing two tripeptides (valine-proline-proline and isoleucine-proline-proline), on blood pressure (BP). METHODS: A total of 46 borderline hypertensive men aged 23 to 59 years were recruited at their workplace for this trial. Subjects were randomly allocated into two groups; sour milk drink group (S-group, n = 23) and placebo (acidified milk) drink group (P-group, n = 23) for 4 weeks. Blood pressure was measured twice at each occasion by a physician, at the health center of the company, with a mercury at baseline, 2 and 4 weeks. Statistical analysis was performed by SPSS 10.0J. RESULTS: The S-group and P-group showed no significant difference in baseline systolic BP (mean [SD], S: 147.6 [9.6], P: 145.3 [13.0]) or diastolic BP (S: 95.3 [9.9], P: 91.5 [9.6]). In the S-group, change in systolic BP at 2 and 4 weeks were -4.3 mm Hg (95% confidence interval [CI] -8.3 to -0.4; P = .032) and -5.2 mm Hg (95% CI -10.1 to -0.3; P = .039), both statistically significant. Diastolic BP showed change from -1.7 mm Hg (95% CI -5.4 to 2.0) at 2 weeks and -2.0 (95% CI -5.4 to 1.5) at 4 weeks, respectively. In the P-group, change in systolic BP were -0.5 (95% CI -5.8 to 4.8) at 2 weeks and -3.7 (95% CI -8.3 to 0.9) and change in diastolic BP were -0.6 (95% CI -4.7 to 3.6) and -0.3 (95% CI -3.9 to 3.3), which were not statistically significant. CONCLUSIONS: This trial demonstrated the beneficial effect of sour milk on BP in borderline hypertensive men who were not taking antihypertensive medication. 相似文献
6.
Eri Hara Motoki Ueda Akira Makino Isao Hara Eiichi Ozeki Shunsaku Kimura 《ACS medicinal chemistry letters》2014,5(8):873-877
l-lactic acid)30 (AB-type), which accumulates in solid
tumors through the enhanced permeability and retention (EPR) effect.
However, lactosome on multiple administrations changed its pharmacokinetics
from accumulation in tumors to liver due to the production of antilactosome
IgM, which was triggered by the first administration. This phenomenon
is called the accelerated blood clearance (ABC). In order to reduce
the production of antilactosome IgM, a novel nanoparticle composed
of (poly(sarcosine)23)3-block-poly(l-lactic acid)30 (A3B-type)
was prepared. The A3B-type lactosome at the second administration
showed an in vivo disposition similar to that at
the first administration due to suppression of antibody production.
This study involving the AB- and A3B-type lactosomes, with
variation of conditions, revealed that the high local density of poly(sarcosine)
chains of the A3B-type lactosome should relate to the prevention
of a polymeric micelle from interacting B-cell receptors. 相似文献
7.
Atsushi Kasamatsu Masashi Shiiba Dai Nakashima Ken Shimada Morihiro Higo Takashi Ishigami Shunsaku Ishige Katsunori Ogawara Hideki Tanzawa Katsuhiro Uzawa 《Oral and maxillofacial surgery》2013,17(1):63-66
Background
Myoepithelioma, a generally benign tumor comprised of myoepithelial cells, is an uncommon salivary gland tumor. Among four morphologic variants of myoepithelioma, epithelioid type has not been reported in the oral and maxillofacial region.Case report
A 61-year-old man first noticed the mass 3 years previously. The oral examination revealed a firm, non-tender, and well-circumscribed mass in the middle of the hard palate. A magnetic resonance imaging scan showed a well-circumscribed mass with low signal intensity (T1-weighted image) or increased signal intensity (T2-weighted image).Discussion
Immunohistochemically, the tumor cells in the present case reacted to the epithelial (CK HMW and CAM5.2) and the mesenchymal (vimentin) markers. However, myoepithelial markers (S-100 protein, α-smooth muscle actin, glial fibrillary acidic protein, and calponin), except p63, were not expressed in the tumor cells. These results indicated that the epithelial myoepithelioma cells differentiated into epithelial cells rather than myoepithelial cells. We believe that epithelioid myoepithelioma of the palate is a distinctive subtype of myoepithelioma that should be included in the differential diagnosis of tumors of the palate. 相似文献8.
9.
10.